TCL Archive Neuro-Oncologist Schold Leaves Duke For UPCI; Rosner Leads Institute At Chicago. September 1, 2000
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004